Gaucher's disease is named after the French doctor Philippe Gaucher who first described it in 1882. Gaucher's is a genetic disease in which a fatty substance accumulates in cells and certain organs of the body. Gaucher's is a hereditary deficiency of the enzyme ‘glucocerebrosidase' which acts on a fatty substance ‘glucocerebroside', which accumulates particularly in the white cells. Glucocerebroside collects in the spleen, liver, kidneys, lungs, brain and in bone marrow.
Symptoms of Gaucher's disease
Enlarged spleen and liver
Lymph nodes swelling and joints
Brownish tint in skin
Low blood platelets
Yellow fatty deposits on the white of the eye
Painful bone lesions
Persons with Gaucher's disease are more susceptible to infections.
Gaucher's disease types
Type 1: This is the most common form of the disease which causes enlargement of liver and spleen, causes pain and breaks bones, and also causes lung and kidney problems. However, this does not involve the brain. Type 1 Gaucher's can occur at any age.
Type 2: This can cause severe damage of the brain and it appears mostly among infants. Children affected with Gaucher's die by age 2.
Type 3: Liver and spleen enlargement occur in this type and there are some signs of brain involvement though it is gradual. Although Gaucher's disease has no cure, there are treatment options for types 1 and 3. Enzyme replacement therapy is usually very effective in these types. However, treatment options for type 2 are very minimal.
Causes of Gaucher's disease
As described, Gaucher's disease is a rare and inherited disorder and build up of the enzyme glucocerebroside prevents the other organs in the body to function properly. The carrier rate among Ashkenazi Jews is almost 8.9% while the incidence at birth is 1 in 450. All the three forms of Gaucher's disease are caused by glucocerebrosidase activity deficiency. This is due to mutations in GBA, a structural gene that encodes the enzyme.
Diagnosis of Gaucher's disease
Normally the couples are tested for the Gaucher's disease. Blood samples are diagnosed and the level of enzyme responsible for Gaucher is measured. Gaucher gene can be analyzed at the molecular level. Affected individuals have two Gaucher genes and low enzyme levels when the other is a non carrier. Enzyme testing as a means of carrier identifications for Gaucher's disease is about 90% accurate. As such there could be an overlap in the range of enzyme activity values between non-carriers of the disease and the carriers. Hence, use of direct molecular DNA testing is more reliable and almost 98% accurate.
During pregnancy, all types Gaucher's disease can be detected through procedures called amniocentesis. Prenatal diagnosis is available for those who are at risk for having a child with Gaucher's.
Spleen removal and bone marrow transplants were adopted previously but with substantial risks. Enzyme replacement therapy has been made available recently to combat the underlying problems in Gaucher's disease. Although originally the enzyme has been placentally derived, since 1994 Cerezyme, a recombination of form of acid beta glucosidose, which is FDA approved has been used for the treatment of symptomatic Gaucher's disease. Here regular intravenous infusion of enzyme which has been biochemically modified is done so as to target the Gaucher cell. However, enzyme therapy is complicated as the minimal effective dosage and optimal frequency of administration has not been established. Therefore, it calls for a very careful and coordinated management by physicians with special expertise in Gaucher's disease.
The spleen is responsible for the production of humoral antibodies and is a reservoir for blood cells. In case of Splenomegaly, the functions associated with the spleen are hampered. Enlarged spleen or Splenomegaly generally indicates the presence of an underlying medical condition which has to be attended to immediately. Physicians palpate the patient and observe the size variation that is clinically correlated with Splenomegaly. This routine examination is followed by other diagnostic tests which include blood, urine and body fluid analysis to identify the presence of infection.
Symptoms of Splenomegaly
The occurrence of Splenomegaly is usually asymptomatic unless there is an underlying factor such as bacterial, viral or parasitic infection. In most cases, patients complain of upper abdominal discomfort or pain, decreased appetite, weakness because of anemia and susceptibility to infections.
Splenomegaly predominantly occurs because of infections. However other metabolic disorders such as Niemann pick and Gaucher's disease can also serve as diagnostic markers. The susceptibility of Splenomegaly is high among children and elderly persons. Enlarged spleen can be life threatening as it may lead to splenic rupture in the abdominal cavity.
Treatment options for Splenomegaly include treating the underlying infection by administration of antibiotics. Post operative patients must be given antibiotics such as penicillin to avoid relapse of infections. In case of splenic enlargement, contact sports such as football, wrestling, boxing must be avoided. Children must be given vaccinations for Pneumococci, Haemophilus influenza (Bacillus Influenzae) on schedule to avoid infections. Splenectomy is the surgical choice in cases of total spleen malfunction or rupture.
Bibliography / Reference
Collection of Pages - Last revised Date: February 16, 2019